FDA approves Janssen’s twice-yearly antipsychotic for schizophrenia
The approval is based on data from the Phase III trial, where 92.5% of the patients on Invega Hafyera did…

The approval is based on data from the Phase III trial, where 92.5% of the patients on Invega Hafyera did…
Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it…
ByBiogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor…
The UK’s pricing regulator the National Institute for Health and Clinical Excellence (NICE) has decided to not recommend Janssen’s Spravato…
BySecuado is the first and only transdermal patch formulation to be approved for treating schizophrenia.
ByIn March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for…
BySpravato is estimated to cost $198,000 per quality-adjusted life year (QALY) gained, exceeding the commonly cited cost-effectiveness thresholds of between…
ByPTSD is an indication with limited pharmacological treatment options.
ByThank you for subscribing to Pharmaceutical Technology